Xanodyne Pharmaceuticals files to go public
WASHINGTON Nov 9 (Reuters) - Xanodyne Pharmaceuticals Inc filed with regulators on Friday to raise up to $86.25 million in an initial public offering of common stock.
The drug company said in a registration statement with the U.S. Securities and Exchange Commission that Morgan Stanley and Deutsche Bank Securities were the lead underwriters for the IPO.
Xanodyne plans to list its stock on the Nasdaq under the symbol "XANO" (XANO.O). (Reporting by Karey Wutkowski, editing by Leslie Gevirtz)